Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment …

AB Cuéllar-Barboza, SL McElroy, M Veldic… - International Journal of …, 2020 - Springer
Background Treatment in bipolar disorder (BD) is commonly applied as a multimodal
therapy based on decision algorithms that lack an integrative understanding of molecular …

Pharmacogenomics of bipolar disorder

G Severino, A Squassina, M Costa, C Pisanu… - …, 2013 - Taylor & Francis
Bipolar disorder (BD) is a lifelong severe psychiatric condition with high morbidity, disability
and excess mortality. The longitudinal clinical trajectory of BD is significantly modified by …

Towards the clinical implementation of pharmacogenetics in bipolar disorder

NC Salloum, MJ McCarthy, SG Leckband, JR Kelsoe - BMC medicine, 2014 - Springer
Background Bipolar disorder (BD) is a psychiatric illness defined by pathological alterations
between the mood states of mania and depression, causing disability, imposing healthcare …

[HTML][HTML] Pharmacogenomic aspects of bipolar disorder: An update

M Budde, D Degner, J Brockmöller… - European …, 2017 - Elsevier
The hopes for readily implementable precision medicine are high. For many complex
disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in …

Pharmacogenomic characterization in bipolar spectrum disorders

S Fortinguerra, V Sorrenti, P Giusti, M Zusso, A Buriani - Pharmaceutics, 2019 - mdpi.com
The holistic approach of personalized medicine, merging clinical and molecular
characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily …

The experience of bipolar disorder: a personal perspective on the impact of mood disorder symptoms

J Licinio - Molecular psychiatry, 2005 - nature.com
This is a personal perspective on bipolar disorder, entirely written by a well-informed patient
who is a successful mental heath professional. The patient prefers to remain anonymous; …

New “drugs and targets” in the GWAS era of bipolar disorder

HX Qi, X Xiao, T Li, M Li - Bipolar Disorders, 2023 - Wiley Online Library
Objective Due to the phenotypic heterogeneity and etiological complexity of bipolar disorder
(BD), many patients do not respond well to the current medications, and developing novel …

The role of pharmacogenomics in bipolar disorder: moving towards precision medicine

C Pisanu, U Heilbronner, A Squassina - Molecular diagnosis & therapy, 2018 - Springer
Bipolar disorder (BD) is a common and disabling psychiatric condition with a severe
socioeconomic impact. BD is treated with mood stabilizers, among which lithium represents …

The role of pharmacogenetic testing in the treatment of bipolar disorder: preliminary results

M Ielmini, N Poloni, I Caselli, M Diurni… - Minerva …, 2018 - irinsubria.uninsubria.it
BACKGROUND: Bipolar disorder is a frequent cause of disability and healthcare costs.
Variability in outcome leads to a large number of treatment failures, typically followed by a …

[HTML][HTML] Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder

A Squassina, M Manchia… - Human genomics and …, 2010 - ncbi.nlm.nih.gov
Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by
manic and depressive episodes. Among the most effective treatments, mood stabilizers …